Le Lézard
Classified in: Health
Subjects: ASI, DEI

Oncomine Dx Target Test Receives MHLW Approval as a Companion Diagnostic for Eli Lilly's RET-Inhibitor in Non-Small Cell Lung Cancer in Japan


CARLSBAD, Calif., Sept. 10, 2021 /PRNewswire/ -- Thermo Fisher Scientific today announced the Japan Ministry of Health, Labour and Welfare (MHLW), Japan's regulatory agency, has granted approval for the Oncomine Dx Target Test as a next-generation sequencing (NGS)-based companion diagnostic (CDx) for patients with RET-fusion positive non-small-cell lung cancer (NSCLC) who may be treated with Eli Lilly and Company's selpercatinib (formerly known as LOXO-292). The MHLW granted orphan drug designation for selpercatinib, a tyrosine kinase inhibitor that selectively binds to the RET receptor, in 2020.

"This approval will help patients suffering from non-small cell lung cancers whose tumors are positive for fusions in the RET receptor, providing access to new, potentially more effective treatments," said Hiroo Murota, vice president and general manager, Thermo Fisher Scientific Japan. "We will continue to advance precision medicine by expanding our companion diagnostic tests that identify biomarkers associated with targeted therapies."

Thermo Fisher currently offers the only globally-distributable NGS companion diagnostic solution approved and reimbursed by government and commercial insurers in more than 15 countries, including the U.S., multiple European nations, Japan, South Korea and the Middle East, covering more than 550 million lives globally.

Thermo Fisher's Oncomine Dx Target Test now has approvals in Japan for five biomarkers with a total of ten associated targeted therapies for NSCLC patients. The CDx markers and therapies include:

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.

Thermo Fisher Scientific logo (PRNewsfoto/Thermo Fisher Scientific)

Media Contact Information:

Mauricio Minotta
Phone: 760-805-5266
Email: [email protected]

Jen Heady
Phone: 617-275-6547
Email: [email protected]

 

SOURCE Thermo Fisher Scientific


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...



News published on and distributed by: